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Abstract
A global loss of cytosine methylation in DNA has been implicated in a wide range of diseases. There is growing evidence
that modifications in DNA methylation can be brought about by altering the intake of methyl donors such as folate. We
examined whether long-term daily supplementation with 0.8 mg of folic acid would increase global DNA methylation
compared with placebo in individuals with elevated plasma homocysteine. We also investigated if these effects were
modified by MTHFR C677T genotype. Two hundred sixteen participants out of 818 subjects who had participated in a
randomized double-blind placebo-controlled trial were selected, pre-stratified on MTHFR C677T genotype and matched on
age and smoking status. They were allocated to receive either folic acid (0.8 mg/d; n = 105) or placebo treatment (n = 111)
for three years. Peripheral blood leukocyte DNA methylation and serum and erythrocyte folate were assessed. Global DNA
methylation was measured using liquid chromatography-tandem mass spectrometry and expressed as a percentage of 5-
methylcytosines versus the total number of cytosine. There was no difference in global DNA methylation between those
randomized to folic acid and those in the placebo group (difference = 0.008, 95%CI =20.05,0.07, P = 0.79). There was also no
difference between treatment groups when we stratified for MTHFR C677T genotype (CC, n = 76; CT, n = 70; TT, n = 70),
baseline erythrocyte folate status or baseline DNA methylation levels. In moderately hyperhomocysteinemic men and
women, long-term folic acid supplementation does not increase global DNA methylation in peripheral blood leukocytes.
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Introduction
Disturbances in DNA methylation, one of several epigenetic
mechanisms, have been implicated in many diseases ranging from
cancers to cardiovascular disease. Two main types of changes in DNA
methylation patterns have been observed – global hypomethylation
[1], and regional hypermethylation, particularly in the promoter
regions of certain genes such as tumor suppressor genes or imprinted
genes [2,3,4]. Global DNAmethylation provides genomic stability and
structure [5] while promoter hypermethylation inhibits the transcrip-
tion of associated genes, resulting in gene silencing [6].
Folate-mediated one-carbon metabolism is key for DNA
methylation as well as for nucleotide synthesis, and DNA repair
and stability. Folate, a water soluble B-vitamin, functions as a
donor and acceptor of one-carbon units in its various forms in
cellular metabolism. As such, manipulation of intake of folate or
other factors involved in one-carbon metabolism can largely
influence DNA methylation, and methyl-deficient and repletion
diets have been shown to alter global DNA methylation patterns in
animal studies [7] and also in human studies [8,9] although the
evidence is not unequivocal [10,11].
Many factors affect the availability of methyl groups in folate-
mediated one-carbon metabolism. One of the most extensively
studied genetic polymorphisms which can modify folate metabo-
lism is the 677CRT polymorphism of the gene that codes for the
enzyme methylenetetrahydrofolate reductase (MTHFR). Methy-
lenetetrahydrofolate reductase converts 5,10-methylenetetrahy-
drofolate to 5-methyltetrahydrofolate, which is required for the
conversion of homocysteine to methionine. Rates of folate
metabolism have been shown to differ between those who have
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the TT genotype compared to those with the CC genotype;
production of methyl group donors is higher in those with the CC
genotype compared to those with the TT genotype [12].
Indeed, on a functional level, since homocysteine has to be
remethylated to form methionine, individuals with the MTHFR
677TT polymorphism have higher concentrations of plasma
homocysteine when folate status is low compared to those with the
other two genotypes [13,14]. MTHFR 677TT individuals were
also found to have lowered DNA methylation in their leukocytes
when folate status is low compared to those who have the
MTHFR 677CC genotype [15].
Given the importance of DNA methylation in epigenetic
regulation, and the documented effects of experimental folate
deprivation and repletion, it is relevant to know the ways in which
folic acid supplementation impacts DNA methylation. We
investigated whether daily supplementation of 800 mg folic acid
for 3 years would increase global DNA methylation in peripheral
blood leukocytes compared with placebo in individuals with
elevated homocysteine concentrations. In addition, we addressed
effects separately in strata of the MTHFR C677T genotypes.
Materials and Methods
Ethics Statement
The study protocol was approved by the Medical Ethics
Committee of Wageningen University. All participants gave
written informed consent.
Study Participants
Participants were a subset of Dutch men and post-menopausal
women aged 50–70 years from a central-eastern region of the
Netherlands and who had participated in the Folic Acid and
Carotid Intima-media Thickness (FACIT) trial [16]. The FACIT
trial was designed to investigate the effect of folic acid
supplementation on atherosclerotic progression. Additional out-
comes of the trial were age-related decline in cognitive function
and hearing [17,18,19]. Here we present data for the effect of folic
acid on global DNA methylation for a subset of participants.
Detailed participant recruitment for this randomized double blind
placebo-controlled trial has been described previously [17]. Briefly,
participants were recruited using municipal and blood-bank registries
and randomized between November 1999 and April 2001. Inclusion
criteria were plasma total homocysteine concentrations between
13 mmol/L and 26 mmol/L, vitamin B12 less than 200 pmol/L, no
intestinal disease, and no current use of B-vitamin supplements or
other medications that could influence folate metabolism or
atherosclerotic progression. Finally, more than 80% self-reported
compliance during a 6-week placebo run-in period was required.
After the initial measurement sessions, participants were
randomly allocated to treatment of 800 mg folic acid per day or
placebo with permuted blocks of sizes four and six, which varied
randomly. Specialized staff who were not involved in the study
allocated and labeled the capsule boxes with participants’ unique
sequence number. Those participants in the same household
received the same treatment. The folic acid and placebo capsules
were produced by Swiss-Caps Benelux (Heerhugowaard, Nether-
lands) and were identical in appearance. Capsules were individually
packaged in foil strips containing 28 capsules per strip with the days
of the week printed on the back. Every year, participants received a
13-month supply of capsules. Compliance was determined by
capsule-return counts and a diary that registered missed capsules.
Diaries and capsules were returned by participants every 12 weeks.
For the present study, changes in global DNA methylation were
assessed from stored frozen aliquots from a sub-sample of the
FACIT trial participants. Using only the data from the
participants who had completed the study (n = 818), participants
in the folic acid arm of the trial were pre-stratified by MTHFR
C677T genotype and matched to participants in the placebo arm
on age and current smoking status. Subjects were matched on
these variables because they are thought to influence global DNA
methylation [20,21,22,23,24,25]. Additionally, sampling was done
such that each group of MTHFR C677T genotype was of the
same size. This was done to increase our power of hypotheses
testing related to the genotypes and their effects on global DNA
methylation. Initially, 120 folic acid participants were matched to
120 in the placebo group, but 24 samples were not measured due
to human error in sample retrieval.
Laboratory Measurements
Fasting venous blood was processed and samples were stored at
280uC.Wemeasured serum folate, erythrocyte folate, serum vitamin
B12, plasma total homocysteine, plasma vitamin B6 (pyridoxal 59-
phosphate (PLP)), in addition to serum creatinine and lipids as
described elsewhere [16]. In brief, serum and erythrocyte folate and
serum vitamin B12 were measured using a chemiluminescent
immunoassay (ImmuliteH 2000, diagnostic Products Corporation).
Erythrocyte folate measurements were done in duplicate. Plasma
homocysteine was determined with high performance liquid
chromatography (HPLC) and fluorimetric detection [26]. Vitamin
B6 was measured by HPLC. DNA was extracted from blood
leukocytes and the C677T polymorphism in the methylenetetrahy-
drofolate reductase (MTHFR) gene was determined by PCR and
restriction digest with HinF1 and attained at the beginning of the
study. Intra- and inter-assay variation coefficients for laboratory
analyses were ,15%. A validated food frequency questionnaire was
used at baseline and after the intervention to estimate dietary folate
intake during the past 3 months [27].
Quantification of global DNA methylation was measured by
liquid chromatography-tandem mass spectrometry [28]. Global
DNA methylation is expressed as a percentage of 5-methylcyto-
sines versus the total number of cytosines present in the genome.
Statistical Methods
Non-parametric tests were used to compare differences within
groups and between groups before and after the intervention.
Analysis of covariance (ANCOVA) was used to estimate
differences between groups at baseline and after the intervention
and also to compare the effect of supplementation on global DNA
methylation adjusted for baseline DNA methylation and covari-
ates. Medians, inter-quartile ranges, and 95% confidence intervals
are presented. The variables on which subjects were matched (i.e.
age and current smoking status) were used as covariates in our
model. We performed subgroup analyses for those with deficient to
low-normal erythrocyte folate status at baseline and those with low
and high baseline DNA methylation. We also tested if the effect of
folic acid on global DNA methylation was modified by MTHFR
C677T genotype, age, current smoking status, alcohol intake, body
mass index (BMI), and sex. Previous literature suggests that BMI
may be associated with global DNA methylation [29,30] and sex
has been shown to influence DNA methylation [31,32,33]. There
was no missing data on any of our outcome variables. Differences
were considered significant at P,0.05. All analyses were
computed using SAS version 9.2 (SAS Institute Inc., Cary, NC).
Results
Two hundred sixteen participants (folic acid n= 105 and
placebo n= 111) were included in our analyses. Table 1 depicts
Folic Acid Supplementation on DNA Methylation
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the baseline characteristics of the population. There were slightly
more men in the placebo group than in the folic acid group (66.7%
vs. 62.9%), and more current smokers in the folic acid group
(16.2% vs. 13.5%). Concordant with the stratification procedure,
there were roughly equal numbers of people in each MTHFR
C677T genotype for both treatment groups. Folate intake was
similar between the treatment groups, but alcohol consumption
was higher in the folic acid group. Overall, participants had a low
median folate intake (188 mg/day), but there were only 20 serum
folate deficient (#7 nmol/L) individuals and five individuals, who
were deficient based on erythrocyte folate concentrations
(#305 nmol/L).
Table 2 shows the effects of folic acid supplementation on
several metabolites throughout the study. As expected, there were
large increases in serum folate (535% increase), and erythrocyte
folate (207% increase), and a fall in plasma total homocysteine
(21.6% decrease) after the intervention in the folic acid group
compared to placebo (P,0.0001 for all). There were no changes in
dietary folate intake during the course of the intervention.
Median global DNA methylation levels throughout the study
can be found in table 3. There was no significant change in DNA
methylation within treatment groups after three years (folic
acid difference = 0.02, 95%CI=20.05,0.02, P=0.39; placebo
difference = 0.02, 95%CI=20.06,0.01, P=0.62). There was also
no difference in the effect of supplementation after three years
between the two groups (difference = 0.008, 95%CI=20.05,0.07,
P=0.79). There was no significant treatment effect of folic acid on
global DNA methylation for those with less than normal baseline
red blood cell (RBC) folate (#500 nmol/L) (Table 3) when
compared with the placebo group. Additionally, there was no
trend towards higher methylation following supplementation in
those with below median DNA methylation at baseline (median
difference = 0.003, 95%CI=20.06,0.07, P=0.92) compared
with placebo. When we stratified according to MTHFRC677T
genotype, there was no effect of folic acid on global DNA
methylation in any of the genotype subgroups (from Table 3,
P=0.65 for CC, P=0.32 for CT, P=0.45 for TT), nor did we
observe an effect when we stratified according to alcohol intake
(data not shown). Furthermore, for those who were both
MTHFR677TT and having less than normal baseline RBC folate
status, there was also no significant effect of folic acid on global
DNA methylation compared with the placebo group (data not
shown). In other subgroup analyses, there was no difference
overall in global DNA methylation between males and females.
Finally, no differences in global DNA methylation due to folic acid
supplementation were observed when we stratified by age, current
smoking status, body mass index (BMI), or sex (data not shown).
Discussion
In this double-blind randomized controlled trial of daily folic
acid supplementation in a Dutch population with moderately
elevated homocysteine, we did not find any evidence of changes in
global DNA methylation after three years of supplementation.
Those whose genotype has previously been associated with lower
leukocyte DNA methylation, were no exception.
To our knowledge, seven randomized controlled trials have
previously examined the effect of folic acid on global DNA
Table 1. Baseline characteristics of the population.
Folic acid (n =105) Placebo (n =111)
Demographics
Age (years), mean (standard deviation) 60.9 (5.4) 60.9 (5.5)
Sex, male (%) 66 (62.9%) 74 (66.7%)
Education (high, middle, low), n (%) High = 32 (30.5%), middle = 41 (39.1%), low= 32
(30.5%)
High = 25 (22.5%), middle = 43 (38.7%),
low=43 (38.7%)
Dietary factors
Alcohol intake, g/day, median (inter-quartile range) 14.5 (5.5–24.4) 10.3 (3.5–22.0)
Folate intake, mg/day, median ( inter-quartile range ) 185.8 (159.7–220.7) 194.3 (156.0–236.4)
Serum vitamin B12, pmol/L, median ( inter-quartile range ) 295 (259–359) 283 (247–374)
Serum vitamin B6, nmol/L, median ( inter-quartile range ) 31.8 (25.5–41.4) 31.4 (23.7–44.5)
Non-dietary factors
BMI, mean (standard deviation) 26.9 (3.7) 26.4 (4.2)
Current smokers, n (%) 17 (16.2%) 15 (13.5%)
MTHFR C677T genotype, n (%) CC: 36 (34.3%), CT: 36 (34.3%), TT: 33 (31.4%) CC: 40 (36.0), CT: 34 (30.6%), TT: 37 (33.3%)
doi:10.1371/journal.pone.0024976.t001
Table 2. Biochemical measurements throughout the study.
Metabolite Folic acid (n =105) Placebo (n=111) p-value
Serum folate (nmol/L)
Baseline 12.0 (9.9–14.0)1 10.8 (8.5–13.9) 0.01
Year 3 76.3 (53.4–106.0) 12.5 (10.3–16.2) ,0.0001
Erythrocyte folate (nmol/L)
Baseline 682.7 (528.8–895.8) 677.5 (548.2–807.6) 0.37
Year 3 2100.7 (1767.2–2611.2) 679.0 (564.6–864.3) ,0.0001
Dietary folate intake (mg/day)
Baseline 185.8 (159.7–220.7) 194.3 (156.0–236.4) 0.48
Year 3 173.0 (152.0–197.0) 173.0 (146.0–209.0) 0.48
Plasma total homocysteine (mmol/L)
Baseline 12.5 (11.3–14.5) 13.0 (11.4–15.5) 0.24
Year 3 9.8 (8.8–11.0) 13.4 (11.6–15.1) ,0.0001
1values given are median (inter-quartile range).
doi:10.1371/journal.pone.0024976.t002
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methylation (Table 4). Two of these trials were also performed in
cancer-free populations, but were short-term (12 weeks duration),
used supraphysiological doses of folic acid (2 mg folic acid and
20 mg vitamin B12 and 1.2 mg folic acid, respectively), and used
small sample sizes (included 63 and 61 volunteers, respectively
[34,35]. No effect of folic acid on global DNA methylation
in leukocytes was observed in both these studies, which used
[3H] methylation incorporation to assess DNA methylation.
Table 3. Folic acid supplementation on global DNA methylation for the whole study population, for those with less than normal
RBC folate status at baseline, low and high baseline methylation, and stratified by MTHFR C677T genotype.
Whole study population
Folic acid (n=105) Placebo (n =111) Difference (95%CI) p-value
Baseline 4.63 (4.53,4.74)1,2 4.60 (4.51,4.72) 20.01 (20.07,0.05) 0.71
Year 3 4.62 (4.49,4.73) 4.56 (4.56,4.63) 0.004 (20.06,0.07) 0.90
Difference (95%CI) 20.02 (20.05,0.02) 20.02 (20.06,0.01) 0.008 (20.05,0.07) 0.79
p-value 0.39 0.62
Deficient to low-normal RBC folate status (#500 nmol/L)
Folic acid (n=22) Placebo (n =22) Difference (95%CI) p-value
Baseline 4.62 (4.53,4.64) 4.59 (4.51,4.70) 0.039 (20.13,0.21) 0.65
Year 3 4.59 (4.52,4.76) 4.69 (4.52,4.73) 20.046 (20.19,0.10) 0.53
Difference (95%CI) 0.01 (20.09,0.10) 0.04 (20.09,0.13) 20.058 (20.20,0.08) 0.41
p-value 0.81 0.80
Low/high baseline methylation (median split)
Folic acid Placebo Difference (95%CI) p-value
Low ,4.615 n= 48 n = 60
Baseline 4.51 (4.40,4.56)1,2 4.51 (4.42,4.57) 20.002 (20.05,0.04) 0.92
Year 3 4.53 (4.40,4.66) 4.54 (4.45,4.66) 0.003 (20.06,0.07) 0.93
Difference (95%CI) 0.04 (20.01,0.08) 0.02 (20.02,0.08) 0.003 (20.06,0.07) 0.92
p-value 0.045 0.045
High $4.615 n= 57 n = 51
Baseline 4.72 (4.66,4.82) 4.73 (4.66,4.89) 0.02 (20.03,0.10) 0.29
Year 3 4.68 (4.59,4.78) 4.66 (4.54,4.78) 0.02 (20.08,0.14) 0.63
Difference (95%CI) 20.06 (20.09,20.03) 20.08 (20.14,20.02) 0.008 (20.10,0.11) 0.87
p-value 0.002 0.006
MTHFR C677T genotype
Folic acid Placebo Difference (95%CI) p-value
CC n= 36 n = 40
Baseline 4.63 (4.60,4.64) 4.60 (4.57,4.65) 20.035 (20.12,0.05) 0.41
Year 3 4.58 (4.49,4.69) 4.58 (4.51,4.63) 20.035 (20.12,0.05) 0.42
Difference (95%CI) 20.07 (20.13,20.01) 20.06 (20.10,20.01) 20.017 (20.09,0.06) 0.65
p-value 0.02 0.03
CT n= 36 n = 34
Baseline 4.63 (4.56,4.69) 4.54 (4.47,4.64) 20.06 (20.16,0.04) 0.27
Year 3 4.63 (4.57,4.69) 4.66 (4.55,4.70) 0.06 (20.07,0.19) 0.37
Difference (95%CI) 20.01 (20.06,0.04) 0.05 (0.00,0.13) 0.07 (20.06,0.20) 0.32
p-value 0.78 0.10
TT n= 33 n = 37
Baseline 4.64 (4.54,4.71) 4.63 (4.58,4.70) 0.06 (20.05,0.18) 0.29
Year 3 4.62 (4.56,4.72) 4.59 (4.54,4.64) 20.01 (20.14,0.12) 0.86
Difference (95%CI) 0.02 (20.03,0.10) 20.04 (20.09,0.04) 20.04 (20.16,0.07) 0.45
p-value 0.32 0.61
1values are given as median (inter-quartile range).
2global DNA methylation is expressed as a percentage of 5-methylcytosines versus the total number of cytosines present in the genome.
doi:10.1371/journal.pone.0024976.t003
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Additionally, five randomized controlled trials in cancer-related
studies were performed, as a global loss of methylated cytosines is
frequently observed in cancers [36] and continues to be an active
area of research. Two of these studies reported null results [37,38]
and three studies, all of which were carried out in populations with
colorectal carcinomas or adenomas, noted an increase in global
DNA methylation following daily administration with 10 mg,
5 mg, and 400 mg folic acid, respectively [39,40,41]. In these
studies, global DNA methylation was assessed only in colorectal
tissues with the exception of one study that also measured global
DNA methylation in leukocytes in addition to colonic mucosa
[41]. In the latter study, there was a slight increase in global DNA
methylation in peripheral blood leukocytes of individuals taking
folic acid compared to those in the placebo group (P= 0.05), but
not in colonic mucosa of colorectal adenoma patients following
400 mg daily folic acid supplementation for 10 weeks. Their study
was conducted in colorectal adenoma patients, in whom folic acid
metabolism may already be altered, subsequently affecting DNA
methylation, which may explain for our differences in results. Our
findings are aligned with those in other trials with cancer-free
volunteers.
On the other hand, our findings are unexpected, as dietary
folate depletion/repletion studies in women have previously
reported global DNA hypomethylation reversal following folate
repletion [8,9,10]. In the United States, Shelnutt et al. conducted a
separate folate feeding trial of young women aged 20 to 30, who
were either MTHFR677CC or MTHFR677TT, participants were
put on folate depletion diet of 115 mg dietary folate equivalents
Table 4. Overview of all randomized controlled trials of folic acid with global DNA methylation as an endpoint.
CANCER-FREE POPULATION
Study
Number of
participants Dose Duration Endpoint
DNA methylation
assessment
method
Baseline
concentrations of
folate1
Baseline levels of
DNA methylation
Treatment
effect/Outcome
Fenech et al.
1998 [34]
63 volunteers 2 mg folic
acid and
20 mg
vitamin B12
12 weeks Global DNA
methylation in
leukocytes
[3H] methyl
incorporation
RBC folate (nmol/L)
Men 440.0 (20.4);
women 363.8 (17.2)
Intervention
195200 dpm;
placebo 169600
dpm
No effect
Basten et al.
2006 [35]
61 healthy
volunteers
1.2 mg
folic acid
12 weeks Global DNA
methylation in
lymphocytes
[3H] methyl
incorporation
RBC folate (nmol/L)
intervention 552
(469–655), placebo
668 (508–796) [48]
Intervention
17508 dpm;
placebo 16099
dpm
No effect
Present study 216 healthy
volunteers
(elevated Hcy)
800 mg
folic acid
3 years Global DNA
methylation in
leukocytes
Liquid
chromatography-
tandem mass
spectrometry
(LC-ES MS/MS)
RBC folate (nmol/L)
intervention 682.7
(528.8–895.8),
placebo 677.5
(548.2–807.6); serum
folate (nmol/L)
intervention 12.0
(9.9–14.0), placebo 10.8
(8.5–13.9)
Intervention 4.63%
(4.60–4.66), placebo
4.60% (4.58–4.64)
No effect
CANCER POPULATION
Cravo et al.
1994 [39]
22 patients
with colorectal
adenomas or
carcinomas
and 8 healthy
controls
10 mg
folic acid
6 months Global DNA
methylation in
colorectal tissues
[3H] methyl
incorporation
Serum folate (nmol/L)
in intervention group
21.5 (3.8); placebo
group 17.2 (3.6)
Normal-appearing
rectal mucosa from
controls 109000
dpm
Increased global
DNA methylation
Cravo et al.
1998 [37]
20 colorectal
adenoma
patients
5 mg folic
acid
6 months Global
methylation in
colorectal tissues
[3H] methyl
incorporation
Serum folate
(nmol/L) 43.5 (8.3)
237039 dpm No effect
Kim et al.
2001 [40]
20 colorectal
adenoma
patients
5 mg folic
acid
1 year Global DNA
methylation in
colorectal tissues
[3H] methyl
incorporation
Serum folate (nmol/L)
intervention 67.9,
placebo 33.9; RBC
folate (nmol/L)
intervention 793.1,
placebo 600.4
Intervention
220000 dpm;
placebo 220000
dpm
Increased global
DNA methylation
Pufulete et al.
2005 [41]
31 colorectal
adenoma
patients
400 mg
folic acid
10 weeks Global DNA
methylation in
leukocytes and
colorectal tissues
[3H] methyl
incorporation
Serum folate (nmol/L)
intervention 16.7
(12.9–20.8), placebo
18.5 (14.9–22.2); RBC
folate (nmol/L)
intervention 639.0
(514.3–876.9), placebo
716.0 (591.4–840.6)
Leukocytes 748
(672–825) Bq/mg
DNA; colon 602
(515–689) Bq/mg
DNA
Increased global
DNA methylation
Figueiredo
et al. 2009
[38]
388 colorectal
adenoma
patients
1 mg folic
acid
3 years Global DNA
methylation in
colorectal tissues
Bisulfite
pyrosequencing
LINE-1 analysis
RBC folate (nmol/L)
898.2 (16.3); plasma
folate (nmol/L) 20.9 (0.8)
None taken No effect
1conversion factor of 2.266 for folate from ng/mL to nmol/L.
doi:10.1371/journal.pone.0024976.t004
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(DFE)/day for 7 weeks followed by a 7-week folate repletion diet of
400 mg DFE/day. Overall, global DNA methylation (measured
using the liquid chromatography tandem mass spectrometry assay
identical to the one we used in our study) decreased after folate
depletion diet, but following folate repletion with folic acid
supplementation, global DNA methylation significantly increased
only in those with the TT genotype [42,43]. In contrast with these
findings, we did not find an effect of folic acid treatment according
to genotype. As expected, baseline global DNA methylation in this
American population was higher than baseline levels in our study,
which was conducted in the Netherlands, where unlike the United
States, folic acid fortification is not mandatory. Furthermore,
baseline global DNAmethylation in the Shelnutt et al. study was still
higher than global DNA methylation in our population even after 3
years folic acid supplementation. This may be explained in part by
the fact that our study population is substantially older than theirs
and that their study only included women. Given that DNA
hypomethylation seems to increase with age, reversion of DNA
hypomethylationmay be more difficult andmay take longer in older
individuals. Furthermore, there may be differences between the
effects of folic acid supplementation (the synthetic form of folate)
and natural dietary folate supplementation on DNAmethylation, as
folic acid and natural dietary folates enter the folate-mediated one-
carbon metabolism cycle as different folate vitamers and may
impact DNA methylation by uniquely altering metabolic flux of
reactions in folate-mediated one-carbon metabolism.
In a study by Ingrosso et al. [43] that was partly designed to
investigate the effects of folic acid administration on DNA
methylation in men with hyperhomocysteinemia and uremia,
DNA hypomethylation was higher in those with hyperhomocys-
teinemia compared to controls. Following supplementation with
15 mg of 5-methyltetrahydrofolate daily for 8 weeks, this DNA
hypomethylation was reversed, which does not corroborate with
our own findings. Although not a randomized controlled trial, the
study conducted by Ingrosso et al. is insightful in presenting
evidence of a lowering effect of the metabolically active form of
folate on DNA methylation in men with hyperhomocysteinemia.
Our study is not without limitations. Firstly, we restricted the
study population to those likely to benefit from folic acid
supplementation; only those with elevated homocysteine were
selected to participate in the FACIT trial since high homocysteine
is a very sensitive indicator of low folate status. Intuitively, effects
of folic acid supplementation are expected to be most pronounced
in these individuals. We were not able to test whether effects are
different in those with lower homocysteine concentrations. Genetic
variability and other environmental factors and interactions
between any of these also play a large role in folate-mediated
one-carbon metabolism [44] and may subsequently influence
DNA methylation [45]. Furthermore, while our results suggest
that folic acid supplementation does not increase global DNA
methylation, this does not preclude the possibility that folic acid
supplementation has an effect on the methylation of specific
individual genes, possibly in certain tissues. Folic acid supplemen-
tation may also have an effect on DNA methylation in subgroups
of the population, such as those where polymorphisms from other
folate-metabolizing genes have been observed to influence folate
[46] and homocysteine [46,47] concentrations.
Despite these limitations, our study has some noteworthy
strengths. We were able to include two hundred sixteen
participants in our analyses, making this the largest study to date
investigating the effects of folic acid supplementation on global
DNA methylation in healthy volunteers. Furthermore, we were
able to carry out our study prospectively over three years, and this
relatively long duration of folic acid supplementation can give us a
better idea of the longer-term effects of folic acid.
In conclusion, our study shows that daily supplementation with
800 mg folic acid, while increasing folate status in blood, did not
simultaneously alter long-term global DNA methylation in
leukocytes of individuals with elevated homocysteine. The role of
natural and synthetic folates in DNA methylation remains an area
for further research. The relationship between leukocyte DNA
methylation and DNA methylation in specific tissues should also
be explored as well as genetic variability of folate-mediated one-
carbon metabolism genes and other environmental factors that
may have an impact on DNA methylation.
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